Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

<p>Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Roberto Carmagnani Pestana (15294422) (author)
Andere auteurs:	Justin T. Moyers (15047706) (author), Jason Roszik (15017091) (author), Shiraj Sen (15294425) (author), David S. Hong (15019257) (author), Aung Naing (15023555) (author), Cynthia E. Herzog (15012524) (author), Siqing Fu (15047712) (author), Sarina A. Piha-Paul (15294428) (author), Jordi Rodon (15047721) (author), Timothy A. Yap (15028749) (author), Daniel D. Karp (15294431) (author), Apostolia M. Tsimberidou (15294434) (author), Shubham Pant (15122815) (author), Maria A. Zarzour (15294437) (author), Ravin Ratan (15044195) (author), Vinod Ravi (15047730) (author), Robert S. Benjamin (15012521) (author), Alexander J. Lazar (14963562) (author), Wei-Lien Wang (15294440) (author), Najat Daw (15294443) (author), Jonathan B. Gill (15086581) (author), Douglas J. Harrison (15294446) (author), Valerae O. Lewis (15294449) (author), Christina L. Roland (15294452) (author), Shreyaskumar R. Patel (15062448) (author), J. Andrew Livingston (15294455) (author), Neeta Somaiah (14963553) (author), Joseph A. Ludwig (15016911) (author), Anthony P. Conley (15294458) (author), Nelson Hamerschlak (15294461) (author), Richard Gorlick (15019631) (author), Funda Meric-Bernstam (10258780) (author), Vivek Subbiah (8737068) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Drug Targets Precision Medicine Sarcomas
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

SPIRIT schedule of enrollment, interventions, and assessment.
door: Kim Christin Honselmann (21176936)
Gepubliceerd in: (2025)

Participant timeline: Schedule of enrollment, interventions, and assessments.
door: Pierre Angelvy (22683450)
Gepubliceerd in: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
door: Zoe Edwards (3823528)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
door: James S. Wilmott (15008931)
Gepubliceerd in: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
door: James S. Wilmott (15008931)
Gepubliceerd in: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
door: Iris van 't Erve (15054503)
Gepubliceerd in: (2025)

Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
door: Ming Shu (22683656)
Gepubliceerd in: (2025)

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
door: Marianna Carrabotta (8193039)
Gepubliceerd in: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
door: Sebastian Johannes Schober (14971891)
Gepubliceerd in: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
door: Milana A. Bergamino (15038015)
Gepubliceerd in: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
door: David Olayinka Kamson (16617218)
Gepubliceerd in: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
door: David Olayinka Kamson (16617218)
Gepubliceerd in: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
door: Nigel Bundred (15046233)
Gepubliceerd in: (2025)

Table S1. Isometric handgrip force-matched participant demographics and LV morphology.
door: Corey Tomczak (22648301)
Gepubliceerd in: (2025)

Data_Sheet_1_Benchmarking quantum annealing with maximum cardinality matching problems.PDF
door: Daniel Vert (18769933)
Gepubliceerd in: (2025)

<b>Figure S1.</b><b> Cardiac MRI LV volume responses to EX and MMA in</b><b> </b><b>i</b><b>sometric handgrip force-matched-matched males and females</b>
door: Corey Tomczak (22648301)
Gepubliceerd in: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
door: Benjamin K. Wilke (15055112)
Gepubliceerd in: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
door: Benjamin K. Wilke (15055112)
Gepubliceerd in: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
door: Tom Wei-Wu Chen (15053003)
Gepubliceerd in: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
door: Tom Wei-Wu Chen (15053003)
Gepubliceerd in: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
door: Tom Wei-Wu Chen (15053003)
Gepubliceerd in: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
door: Tom Wei-Wu Chen (15053003)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_m6sna8h1skd1kbpd68uj1b6ooe